BR112023004179A2 - Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo - Google Patents
Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmoInfo
- Publication number
- BR112023004179A2 BR112023004179A2 BR112023004179A BR112023004179A BR112023004179A2 BR 112023004179 A2 BR112023004179 A2 BR 112023004179A2 BR 112023004179 A BR112023004179 A BR 112023004179A BR 112023004179 A BR112023004179 A BR 112023004179A BR 112023004179 A2 BR112023004179 A2 BR 112023004179A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- same
- pyrimid
- pyrimidinone compound
- pyrimidinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200119100 | 2020-09-16 | ||
| PCT/KR2021/012616 WO2022060094A1 (ko) | 2020-09-16 | 2021-09-15 | 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004179A2 true BR112023004179A2 (pt) | 2023-04-11 |
Family
ID=80777269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004179A BR112023004179A2 (pt) | 2020-09-16 | 2021-09-15 | Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12590098B2 (https=) |
| EP (1) | EP4215533B1 (https=) |
| JP (1) | JP7824667B2 (https=) |
| KR (1) | KR102673031B1 (https=) |
| CN (1) | CN116137815B (https=) |
| AU (1) | AU2021344164A1 (https=) |
| BR (1) | BR112023004179A2 (https=) |
| CA (1) | CA3190461A1 (https=) |
| IL (1) | IL300920A (https=) |
| MX (1) | MX2023003087A (https=) |
| WO (1) | WO2022060094A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06001098A (es) * | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| BRPI0514738A (pt) | 2004-08-31 | 2008-06-24 | Hoffmann La Roche | derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos |
| UY29439A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| RU2007147917A (ru) * | 2005-06-10 | 2009-07-20 | Айрм Ллк (Bm) | Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| GB201315072D0 (en) | 2013-08-23 | 2013-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| KR102591947B1 (ko) * | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2021
- 2021-09-15 MX MX2023003087A patent/MX2023003087A/es unknown
- 2021-09-15 CA CA3190461A patent/CA3190461A1/en active Pending
- 2021-09-15 JP JP2023515773A patent/JP7824667B2/ja active Active
- 2021-09-15 EP EP21869716.7A patent/EP4215533B1/en active Active
- 2021-09-15 IL IL300920A patent/IL300920A/en unknown
- 2021-09-15 KR KR1020210123331A patent/KR102673031B1/ko active Active
- 2021-09-15 CN CN202180063334.1A patent/CN116137815B/zh active Active
- 2021-09-15 WO PCT/KR2021/012616 patent/WO2022060094A1/ko not_active Ceased
- 2021-09-15 US US18/245,395 patent/US12590098B2/en active Active
- 2021-09-15 BR BR112023004179A patent/BR112023004179A2/pt unknown
- 2021-09-15 AU AU2021344164A patent/AU2021344164A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215533B1 (en) | 2026-02-11 |
| CN116137815A (zh) | 2023-05-19 |
| US20230348474A1 (en) | 2023-11-02 |
| JP7824667B2 (ja) | 2026-03-05 |
| KR20220036895A (ko) | 2022-03-23 |
| EP4215533A4 (en) | 2024-12-18 |
| IL300920A (en) | 2023-04-01 |
| WO2022060094A1 (ko) | 2022-03-24 |
| JP2023541052A (ja) | 2023-09-27 |
| CN116137815B (zh) | 2025-08-19 |
| KR102673031B1 (ko) | 2024-06-07 |
| CA3190461A1 (en) | 2022-03-24 |
| MX2023003087A (es) | 2023-04-14 |
| AU2021344164A9 (en) | 2024-03-21 |
| AU2021344164A1 (en) | 2023-05-04 |
| US12590098B2 (en) | 2026-03-31 |
| EP4215533A1 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4523755A3 (en) | Quinazoline derivatives as antitumor agents | |
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| SA522433129B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| CR20230404A (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| JOP20220332A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| MX2025008920A (es) | Inhibidores de parp1 triciclicos y usos de estos | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| MX2023010491A (es) | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| BR112020020708A8 (pt) | Derivados da ureia cíclica fundidã como antagonista crhr2 | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2025011086A (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| BR112023004179A2 (pt) | Composto de pirimido pirimidinona e composição farmacêutica compreendendo o mesmo | |
| BR112022020865A2 (pt) | Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo |